2. Academic Validation
  3. Neonatal Malignant Disorders: Germ Cell Tumors

Neonatal Malignant Disorders: Germ Cell Tumors

  • Clin Perinatol. 2021 Mar;48(1):147-165. doi: 10.1016/j.clp.2020.11.010.
Rachana Shah 1,  Brent R Weil 2,  Christopher B Weldon 2,  James F Amatruda 3,  A Lindsay Frazier 4
Affiliations

Affiliations

  • 1 Division of Oncology, Department of Pediatrics, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, University of Southern California, Keck School of Medicine, 4650 Sunset Boulevard, MS#54, Los Angeles, CA 90027, USA. Electronic address: [email protected].
  • 2 Department of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Department of Pediatric Oncology, Children's Cancer and Blood Disorders Center, Children's Hospital Dana-Farber Cancer Center, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.
  • 3 Division of Oncology, Department of Pediatrics, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, University of Southern California, Keck School of Medicine, 4650 Sunset Boulevard, MS#54, Los Angeles, CA 90027, USA.
  • 4 Department of Pediatric Oncology, Children's Cancer and Blood Disorders Center, Children's Hospital Dana-Farber Cancer Center, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.
PMID: 33583501 DOI: 10.1016/j.clp.2020.11.010
Abstract

Germ cell tumors (GCTs) comprise a wide spectrum of benign and malignant tumors. Neonatal GCTs are predominantly teratomas (mature or immature), which are typically cured with surgery alone. Relapses are infrequent even in the setting of microscopic residual disease; therefore, negative surgical margins at the cost of significant morbidity are not recommended. In neonates with metastatic malignant disease or malignant disease for which upfront surgical resection is not feasible without significant morbidity, an initial biopsy followed by neoadjuvant chemotherapy and delayed surgical resection is recommended. Carboplatin-based regimens should be considered when chemotherapy is indicated.

Keywords

Choriocarcinoma; Fetal; Fetus-in-fetu; Germ cell tumor; Molecular genetics; Neonatal; Teratoma; Yolk sac tumor.

Figures